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Abstract
 
We have previously shown that hepatitis B virus (HBV) replication is abolished in the liver of
HBV transgenic mice by inflammatory cytokines induced by HBV-specific cytotoxic T cells
and during unrelated viral infections of the liver. We now report that intrahepatic HBV repli-
 
cation is also inhibited in mice infected by the malaria species 
 
Plasmodium yoelii
 
 17X NL. 
 
P.
yoelii
 
 infection triggers an intrahepatic inflammatory response characterized by the influx of
 
natural killer cells, macrophages, and T cells. During this process, interferon (IFN)-
 
g
 
 and IFN-
 
a
 
/
 
b
 
 suppress HBV gene expression and replication in the liver. Collectively, the data suggest
that malaria infection might influence the course and pathogenesis of HBV infection in coin-
fected humans.
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Introduction
 
The hepatitis B virus (HBV)
 
1
 
 is a noncytopathic, enveloped
virus that causes acute and chronic hepatitis and hepatocel-
lular carcinoma (1). Viral clearance and liver disease during
acute HBV infection are associated with a strong, poly-
clonal, and multispecific CTL response, which is weak or
 
not detectable in patients with chronic hepatitis (1).
 
 
 
We
have reported previously that IFN-
 
g
 
 produced by hepatitis
B surface antigen–specific CTLs is sufficient to inhibit
HBV replication in the liver of HBV transgenic mice (2–
4), and that this process is mediated by nitric oxide (NO)
(5).
 
 
 
We have also demonstrated that HBV replication can
be abolished in these mice in response to inflammatory cy-
tokines, especially IFN-
 
a
 
/
 
b
 
 and IFN-
 
g
 
 that are produced
in the liver during lymphocytic choriomeningitis virus (2,
6), murine cytomegalovirus, and adenovirus (2, 7) infec-
tions. Moreover, we have recently shown that similar cy-
tokine-dependent, noncytopathic antiviral mechanisms can
contribute to viral clearance during acute viral hepatitis in
chimpanzees by purging HBV replicative intermediates
from the cytoplasm and covalently closed circular viral
DNA from the nucleus of infected cells (8). The current
study was performed to see if a similar antiviral process is
induced during 
 
Plasmodium
 
 
 
yoelii
 
 infection in HBV trans-
genic mice, since malaria and HBV coinfection is common
in many parts of the world.
 
Malaria is initiated by 1–10 sporozoites injected into the
host by a female anopheles mosquito. After a short time in
the circulation, each sporozoite infects a hepatocyte within
which they proliferate and develop into the liver stages of
the plasmodial life cycle (9, 10). Eventually, the infected
hepatocytes rupture, releasing hundreds of merozoites that
infect RBCs and initiate the blood stage of the infection
that rapidly spreads and can destroy up to 50% of the RBCs
before the infection is controlled by the immune response
(11). Because merozoites do not infect hepatocytes, the in-
fection is usually self-limited if the blood stage is controlled.
The hepatic and blood stages of malaria are controlled by
Abs, macrophages, and cytokines (12–17) including IFN-
 
g
 
via the induction of NO, TNF-
 
a
 
, IL-1, and IL-6 (18–22).
Th1 and Th2 responses are induced during the blood stage
infection, and the balance between these two subsets plays
a vital role in the outcome of the infection, with a Th1 re-
sponse appearing to be essential for elimination of the para-
sites (23–26). The hepatic stage of the infection is also con-
trolled by CTLs (14–16).
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While coinfection by HBV and malaria is a major public
health problem in large areas of the world, the mutual in-
teractions between the two pathogens are poorly under-
stood. Because inflammatory cytokines are induced during
malaria and contribute to its control, it is possible that the
same cytokines could interfere with HBV replication in the
liver in coinfected individuals. Indeed, high levels of TNF-
 
a
 
,
IFN-
 
g
 
, and IL-6 are detectable in the blood of malaria pa-
tients and in the spleen and liver in rodent models of ma-
laria (11, 27–32). Furthermore, parasitized RBCs are cleared
by resident hepatic and splenic macrophages (33, 34) that
can not only secrete antiviral cytokines but also function as
antigen presenting cells, and produce chemokines that lead
to recruitment of T cells that can secrete their own salvo of
antiviral cytokines in the infected liver.
Since inflammatory cytokines are known to suppress
HBV replication in HBV transgenic mice (3), we predicted
that HBV replication in these animals might be inhibited
during 
 
P
 
. 
 
yoelii
 
 infection. This study was performed to test
that prediction.
 
Materials and Methods
 
Mice.
 
HBV transgenic mouse lineages 1.3.32 and 1.3.46 used
in this study have been described previously (35). Both lineages of
mice replicate HBV at high levels in the liver and kidney without
any evidence of cytopathology. Lineage 1.3.32 was derived from
an outbred founder. It was expanded by repetitive backcrossing
for more than 10 generations against C57BL/6, and then bred 1
generation against BALB/c mice to produce F
 
1
 
 hybrids that were
used in this study. Lineage 1.3.46 was derived from an inbred
B10D2 founder and has been continually expanded on that back-
ground. In the current study, lineage 1.3.46 was backcrossed
against a panel of mice whose IFN-
 
g
 
 (IFN-
 
g
 
2
 
/
 
2
 
) (36), IFN-
 
a
 
/
 
b
 
receptor (IFN-
 
a
 
/
 
b
 
R
 
2
 
/
 
2
 
) (37), TNF-
 
a
 
p55 receptor (TNF-
 
a
 
R
 
2
 
/
 
2
 
)
(38), or inducible nitric oxide synthase (iNOS) (iNOS
 
2
 
/
 
2
 
)
(39) alleles had been knocked out, exactly as described (2, 5).
The IFN-
 
g
 
2
 
/
 
2
 
 and IFN-
 
a
 
/
 
b
 
R
 
2
 
/
 
2
 
 mice were provided, respec-
tively, by Timothy Stewart and Michel Aguet (Genentech, Inc.,
South San Francisco, CA). The TNF-
 
a
 
R
 
2
 
/
 
2
 
 mice were pro-
vided by Tak Mak (University of Toronto, Ontario, Canada).
The iNOS
 
2
 
/
 
2
 
 mice were provided by John Mudgett (Merck Re-
search Laboratories, Rahway, NJ) and John MacMicking and
Carl Nathan (Cornell University Medical College, New York,
NY). The genetic background of the original knockout animals
was 129/Sv/Ev/ 
 
3
 
 C57BL/6. Before mating with the HBV
transgenic mice, the IFN-
 
g
 
2
 
/
 
2
 
 mice had been backcrossed four
to five generations against BALB/c and the IFN-
 
a
 
/
 
b
 
R
 
2
 
/
 
2
 
, and
the TNF-
 
a
 
R
 
2
 
/
 
2
 
 and iNOS
 
2
 
/
 
2
 
 mice had been backcrossed more
than five generations against C57BL/6. The serum from the
1.3.46 
 
3
 
 knockout F
 
1 
 
progeny was tested for hepatitis B e anti-
gen (HBeAg)-positive using a commercially available kit (Abbott
Laboratories). HBeAg-positive F
 
1
 
 mice were backcrossed to the
corresponding parental knockout lineage to produce HBeAg-
positive F
 
2
 
 progeny that were either homozygous or heterozy-
gous for the null allele that was distinguishable by allele-specific
PCR reactions, as described previously (36–39). Thus, the HBV 
 
3
 
knockout animals were genetically heterogeneous with variable
contributions from BALB/c, B10D2, and C57BL/6 parental
strains. In all experiments, the mice were matched for age (8 wk),
sex (male), and serum HBeAg levels before experimental manip-
 
ulation. All animals were housed in pathogen-free rooms under
strict barrier conditions.
 
P. yoelii Infection.
 
The
 
 
 
P. yoelii yoelii 
 
(17X NL nonlethal
strain) was maintained by alternating passage of the parasites in
 
Anopheles stephensi
 
 mosquitoes and in B10.D2 mice, as described
previously (40, 41). Sporozoites were collected 14 d after an infec-
tious blood meal by hand dissection of 
 
P
 
. 
 
yoelii
 
 17 XNL–infected
mosquito salivary glands in M199 medium containing 1% normal
mouse serum (Rockland, Inc.) as described previously (42).
Erythrocytic stage parasites were obtained from heparinized blood
of a previously sporozoite-infected mouse, and maintained by cy-
clic passages of the parasites in congenic mice, as described previ-
ously (43). The parasitized RBCs were collected in equal volume
of HBSS (GIBCO BRL) plus 20% glycerol (Sigma-Aldrich) plus
100 U/ml heparin (Sigma-Aldrich), and kept in liquid nitrogen.
Mice were injected either intravenously with 10
 
6
 
 sporozoites or
intraperitoneally with 10
 
7
 
 parasitized RBCs. Control mice were
injected either with an extract of uninfected salivary glands or
with uninfected RBCs, respectively. Animals were killed at multi-
ple time points after infection, and their livers were harvested for
histological, immunohistochemical, and histochemical analyses
(see below), or they were snap frozen in liquid nitrogen and stored
at –80
 
8
 
C for subsequent DNA and RNA analyses. Parasitemia was
determined by microscopic examination of Giemsa-stained thin
blood smears, obtained from days 1–30 after inoculation.
 
Tissue DNA and RNA Analyses.
 
Frozen liver (left lobe) was
mechanically pulverized under liquid nitrogen, and total genomic
DNA and RNA were isolated for Southern and Northern blot
analyses exactly as described previously (35). Nylon membranes
were analyzed for HBV DNA, HBV RNA, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), and 2
 
9
 
5
 
9
 
-oligoadenylate
synthetase (2
 
9
 
5
 
9
 
-OAS) as described elsewhere (4). Quantification
of iNOS, cytokine, T lymphocyte, and macrophage and neutro-
phil marker mRNAs was performed by RNase Protection assay
exactly as described previously (4, 8, 44). A fragment (nucleotides
124–368) from the mNK1.1 cDNA (Genbank accession number
S43141) was subcloned into a PGEM-T Easy vector (Promega)
using PCR-assisted cloning (44). The vector was linearized and
used for T7 polymerase–directed synthesis of a 
 
32
 
P-labeled anti-
sense RNA probe. The hybridization reactions, RNase treat-
ments, isolations of protected RNA duplexes, and resolution of
protected probes by denaturing PAGE gels were carried out as
described (44). Dried gels were placed on film (XAR; Eastman
Kodak Co.) with intensifying screens for various periods of time
at 
 
2
 
70
 
8
 
C.
 
Biochemical and Histological Analysis.
 
The extent of hepatocel-
lular injury during malaria infection was monitored histologically
and biochemically by measuring serum alanine aminotransferase
(sALT) activity at multiple time points after infection. sALT ac-
tivity was measured in a Paramax chemical analyzer (Baxter Di-
agnostics, Inc.) exactly as described previously (4). For histologi-
cal analysis, liver tissue was fixed in 10% zinc-buffered formalin
(Anatech), embedded in paraffin, sectioned (3 
 
m
 
m), and stained
with hematoxylin and eosin.
 
Results and Discussion
 
P. yoelii Infection: Parasitemia and Liver Disease in HBV
Transgenic Mice.
 
21 age-, sex-, and serum HBeAg-
matched transgenic mice from lineage 1.3.32 were infected
either intravenously with 10
 
6
 
 
 
P
 
. 
 
yoelii 
 
sporozoites (liver
stage), or intraperitoneally with 10
 
7
 
 parasitized RBCs 
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(blood stage), and groups of three mice were killed on days
1, 3, 5, 10, 15, and 20 after infection. Control mice were
injected with either uninfected salivary glands or uninfected
RBCs. The infected animals developed a time-dependent
necroinflammatory liver disease that was detectable histo-
logically starting 1 d after infection and lasted for 10–15 d
until the parasites were no longer detectable in the blood
on day 20 (Fig. 1 A). In keeping with the fact that 10
 
6
 
sporozoites cannot infect more than 10
 
6
 
 hepatocytes (1% of
the hepatocyte population) and that the blood stage para-
sites do not infect hepatocytes, very few hepatocytes were
destroyed during the infection. This was reflected in the
very slight elevation in serum sALT activity that was de-
tectable between days 3 and 10 after liver stage inoculation,
and the even smaller sALT elevation between days 1 and 3
after blood stage inoculation (Fig. 1 A). At the peak of par-
asitemia in both types of infection (day 10), many of the
hepatic macrophages (Kupffer cells) were filled with malaria
pigment derived from ruptured infected erythrocytes, and
at this time a large number of inflammatory foci consisting
 
of Kupffer cells and lymphomononuclear cells were widely
distributed throughout the liver (Fig. 1, B and C). Numer-
ous pigment-laden macrophages surrounded by lympho-
mononuclear cells were present (Fig. 1 C, inset). The his-
tological features of the disease are strikingly similar in both
the sporozoite and merozoite infections, suggesting that the
inflammatory process in the sporozoite-infected animals
was probably due primarily to the blood stage of that infec-
tion, although small numbers (
 
z
 
10
 
6
 
 or 
 
z
 
1% of total) of
hepatocytes were destroyed by the sporozoites in the liver
stage infection, as suggested by the slightly higher sALT ac-
tivity in that infection (Fig. 1 A). Finally, the histopatholog-
ical features of the liver disease during either the liver or the
blood stage of infection were not influenced by the genetic
background of the animals, since in independent experi-
ments we showed very similar results after malaria infection
of C57BL/6, B10.D2, and BALB/c mice (not shown).
 
P. yoelii Infection: Effect on HBV Gene Expression and Rep-
lication.
 
Northern and Southern blot analyses were per-
formed to compare the levels of HBV RNA and replicative
Figure 1. Parasitemia and liver disease after P. yoelii infection of HBV transgenic mice. Age-, sex-, and serum HBeAg-matched HBV transgenic mice (lin-
eage 1.3.32) were injected either intravenously with 106 sporozoites (liver stage), or intraperitoneally with 107 parasitized RBCs (blood stage) of P. yoelii yoelii
strain 17X NL, and three mice per group were killed on days 1, 3, 5, 10, 15, and 20 after infection, as indicated. Control mice (time 0) were injected with
either uninfected salivary glands or uninfected RBCs. The mean percentage of blood parasitemia and the mean sALT activity (expressed in U/liter), mea-
sured at the time of autopsy, are indicated for each group of mice (A and C). Hematoxylin and eosin–stained liver sections (original magnification: 3400; bar,
25 mm) from animals killed 10 d after either liver stage infection (B) or blood stage infection (D) was performed. Inset, original magnification: 3600; bar, 35
mm. These experiments have been reproduced twice for the liver stage and three times for the blood stage with identical results. p.i., post infection.532 Malaria Infection Inhibits HBV Replication and Gene Expression in Transgenic Mice
HBV DNA forms in P. yoelii–infected mice and in age- and
sex-matched transgenic controls. After extraction, total he-
patic RNA and DNA from three mice per group were
pooled for analysis. As shown in Fig. 2 (A and B), hepatic
HBV RNA and replicative DNA forms were slightly re-
duced on day 1 after liver stage infection while they were
unchanged at this time after blood stage infection. Corre-
spondingly, 2959-OAS mRNA, a type 1 IFN-inducible
gene, TNF-a mRNA, iNOS mRNA, as well as the mac-
rophage marker F4/80 were slightly induced in the liver
stage but not the blood stage infection, and IFN-g, CD3,
CD4, CD8, and NK1.1 mRNAs were not increased (Fig.
2 C). These results indicate that macrophages are the likely
source of the IFN-a/b, TNF-a, and iNOS detected on
day 1, especially since they are known to produce these
factors upon activation (45).
By day 3, hepatic HBV RNA and DNA were strongly
reduced in both liver stage and blood stage infected mice.
In the liver stage infection, this was accompanied by a
strong induction of IFN-g and iNOS mRNA and a slight
further increase in 2959-OAS and TNF-a mRNA even
though T cell markers were unchanged and NK cell mark-
ers were only slightly increased. In contrast, on day 3 of the
blood stage infection, IFN-g and iNOS mRNAs were
much less strongly induced than in the liver stage infection,
even though the T cell and macrophage markers were
more strongly induced. In addition, 2959-OAS and NK cell
mRNAs were relatively more abundant in these mice than
in the liver stage infection. The relatively strong induction
of IFN-g after liver stage infection suggests that the resi-
dent and/or recruited intrahepatic population of NK,
NKT, and T cells may have become activated to produce
the cytokines at this time. The induction of iNOS mRNA
suggests that the macrophages were further activated at this
time point, presumably due to the increased levels of IFN-g
in the liver.
On day 5 after both infections, HBV replication and
HBV gene expression remained suppressed, especially in
the liver stage infection where 2959-OAS mRNA was very
strongly induced, and where NK1.1 mRNA was more
prominent and T cell markers were strongly enhanced.
Not surprisingly, this was associated with the continued ex-
pression of iNOS, IFN-g, and TNF-a. In both infections,
the T cell and macrophage response, as well as IFN-g and
TNF-a gene expression, continued through day 10 when
the parasitemia was at its peak (Fig. 1 A) and HBV replica-
tion was most profoundly suppressed. By day 15, the para-
sites were almost completely cleared from the circulation,
and cytokine, macrophage, T cell markers, and sALT activ-
ity returned toward baseline levels, as did the hepatic con-
tent of HBV DNA and HBV RNA. All of these events
were completed by day 20.
In summary, while the histological features of the two
infections are quite similar, the liver stage infection ap-
peared to trigger an early T cell–independent cytokine re-
sponse as well as a delayed cytokine response that coincided
with the infiltration of T cells. In contrast, the T cell re-
sponse occurred earlier in the blood stage than in liver stage
infection, perhaps because parasitemia was detectable ear-
lier in those animals, and a T cell–independent phase was
not observed, perhaps indicating that it was induced prima-
rily by infected hepatocytes. In both cases, however, the
induced cytokine responses were associated with a decrease
in HBV RNA and DNA in the liver.
P. yoelii–induced Suppression of HBV Replication Is Mediated
by IFNs. Since IFN-g, TNF-a, 2959-OAS, and iNOS
gene expression coincided with HBV downregulation in
Figure 2. P. yoelii infection inhibits hepatic HBV replication and in-
duces the expression of cytokine genes and inflammatory-cell markers in
the liver. Age-, sex-, and serum HBeAg-matched HBV transgenic mice
(lineage 1.3.32) were injected either intravenously with 106 sporozoites
(liver stage) or intraperitoneally with 107 parasitized RBCs (blood stage)
of P. yoelii yoelii strain 17X NL, and livers were harvested from each of
three mice killed on days 1, 3, 5, 10, 15, and 20 after infection, as indi-
cated. Control mice (time 0) were injected with either uninfected salivary
glands or uninfected RBCs. Northern blot analysis (A) was performed
with total liver RNA pooled from three mice in each group. The mem-
brane was cohybridized with 32P-labeled HBV– and GAPDH–specific
DNA probes. The steady-state HBV and GAPDH mRNA content was
compared with total hepatic RNA from control mice. Bands correspond-
ing to the 3.5- and 2.1-kb HBV mRNAs are indicated. Southern blot
analysis (B) was performed with 30 mg of total liver DNA isolated from
the same pool of mice. All DNA samples were treated with RNase A be-
fore their concentrations were determined. Bands corresponding to the
integrated transgene and the relaxed circular (RC) and single-stranded
(SS) HBV DNA replicative forms are indicated. The integrated transgene
can be used to normalize the amount of DNA bound to the membrane.
The membrane was hybridized with a 32P-labeled HBV–specific DNA
probe. Total liver RNA from the same mice was analyzed by Northern
blot analysis for the expression of 2959-OAS (C), a marker of IFN-a/b
induction. The housekeeping enzyme GAPDH was used to normalize
the amount of RNA loaded in each lane, and its expression was uniform
in all mice (not shown). Total hepatic RNA from the same Plasmodium-
infected transgenic mice was also analyzed by RNase Protection (C) for
the expression of IFN-g, TNF-a, and iNOS transcripts, and for the ex-
pression of CD3g, CD4, CD8, NK1.1, and F4/80, as indicated. The
mRNA encoding the ribosomal protein L32 was used to normalize the
amount of RNA loaded in each lane. These experiments have been re-
produced twice for the liver stage and three times for the blood stage with
identical results.533 Pasquetto et al.
the foregoing experiment, and since we have previously
shown that the corresponding cytokines and NO inhibit
HBV replication under other experimental conditions (2–
7), we monitored the ability of P. yoelii merozoites to in-
hibit HBV replication in HBV transgenic mice whose abil-
ity to produce IFN-g or iNOS, or to respond to TNF-a or
IFN-a/b had been knocked out. Groups of four age-, sex-,
and HBeAg-matched transgenic mice that were either
homozygous or heterozygous for each of these null alleles
were injected intraperitoneally with 107 merozoite-infected
RBCs to initiate a blood stage infection. 10 d after infec-
tion, their livers were harvested and total hepatic DNA and
RNA were extracted and subjected to Southern blot analy-
sis for HBV DNA, Northern blot analysis for 2959-OAS
mRNA, and RNase Protection assays for cytokine, F4/80,
and T cell mRNA content. Since each mouse in each
group of four mice showed identical results, two represen-
tative mice per group are shown in Fig. 3. As expected,
HBV replication was abolished in all of the heterozygous
control mice (represented by the IFN-a/b1/2 heterozy-
gous animals in Fig. 3 A), coinciding with induction of
2959-OAS, TNF-a, IFN-g, and T cell mRNAs (Fig. 3 B).
Importantly, HBV replication was not suppressed in the
IFN-g knockout mice, despite the induction of 2959-OAS;
it was only slightly suppressed in the absence of the IFN-a/b
receptor, despite the induction of IFN-g. These results
suggest that IFN-g and IFN-a/b act independently to in-
hibit HBV replication after P. yoelii infection. Surprisingly,
HBV replication was inhibited in the absence of both
iNOS and the TNFp55 receptor, indicating that neither
NO nor TNF-a receptor–mediated signaling contributes
substantially to the antiviral effect of the merozoites as long
as IFN-a/b and IFN-g are expressed in the liver. The sur-
prising apparent irrelevance of TNF-a might be explained
by the fact that 2959-OAS (i.e., IFN-a/b) and IFN-g are
hyperinduced in these animals, suggesting that, at these lev-
els, the IFNs might compensate for the absence of TNF-a
and be sufficient to downregulate HBV independently.
The fact that the IFN-g–associated antiviral effect was not
seen in the iNOS knockout mice (Fig. 3) was also surpris-
ing, since the IFN-g–dependent inhibition of HBV repli-
cation by CTLs is mediated by NO (4). This is compatible
with two interpretations. First, the antiviral effect in those
animals could be mediated by IFN-a/b since the 2959-
OAS mRNA was strongly induced, and we have shown
that the antiviral effect of IFN-a/b is NO independent.
Alternatively, the IFN-g–dependent antiviral effect trig-
gered by P. yoelii might not be mediated by NO. This
would be consistent with reports that certain IFN-g–depen-
dent effects are mediated by NO-independent mechanisms
(46, 47). This putative activity could be enhanced by the
fact that IFN-g and TNF-a appear to be hyperinduced in
these mice.
In summary, we report that HBV replication and gene
expression are inhibited during P. yoelii infection which ul-
timately clears HBV virions from the liver by triggering an
inflammatory response and the induction of IFN-g, IFN-
a/b, TNF-a, and iNOS in the liver. While all of these cy-
tokines probably function collectively to inhibit HBV rep-
lication, it appears that IFN-g and IFN-a/b are essential,
and that TNF-a and iNOS are dispensable for the antiviral
effect to occur. Since merozoite infection is sufficient to in-
hibit HBV replication in these mice, and since hepatocytes
are not infected by the blood stages of the parasite, the an-
tiviral effect of malaria is likely to be triggered principally
by phagocytosis of infected erythrocytes by Kupffer cells,
leading to their activation and production of chemokines
that recruit NK cells, NKT cells, and malaria-specific T
cells, all of which probably produce inflammatory cyto-
kines that eliminate HBV from the hepatocytes.
These results suggest that similar antiviral events may limit
HBV infection during human malaria infection, especially
Figure 3. Early suppression of HBV replication by malarial infection is
mediated by IFNs. Groups of four age-, sex-, and serum HBeAg-matched
HBV transgenic mice (lineage 1.3.46) knocked out for IFN-g, IFN-a/b
receptor, TNF-a, or iNOS genes were injected intraperitoneally with
107 parasitized RBCs of P. yoelii yoelii strain 17X NL, and livers were har-
vested from each of four mice killed on day 10 after infection. Southern
blot analysis (A) was performed with total liver DNA isolated from two
representative animals in each group. The steady-state HBV content was
compared with total hepatic DNA pooled from four control mice in-
jected with uninfected RBCs (2). All DNA samples were treated with
RNase A before their concentrations were determined. Bands corre-
sponding to the integrated transgene and the relaxed circular (RC) and
single-stranded (SS) HBV DNA replicative forms are indicated. The inte-
grated transgene can be used to normalize the amount of DNA bound to
the membrane. The membrane was hybridized with a 32P-labeled HBV–
specific DNA probe. Total liver RNA (20 mg) from the same pool of
mice was analyzed by Northern blot analysis for the expression of 2959-
OAS (B), a marker of IFN-a/b induction. The housekeeping enzyme
GAPDH was used to normalize the amount of RNA loaded in each lane.
Total hepatic RNA (5 mg) from the same Plasmodium-infected transgenic
mice was also analyzed by RNase Protection (B) for the expression of
IFN-g, TNF-a, and iNOS transcripts, and for the expression of CD3g,
CD4, CD8, NK1.1, and F4/80, as indicated. The mRNA encoding the
ribosomal protein L32 was used to normalize the amount of RNA loaded
in each lane. The sALT activity, measured at the time of autopsy, is indi-
cated for each mouse and is expressed in U/liter. The percentage of blood
parasitemia, measured at the time of autopsy, is indicated for each mouse.
Similar results were obtained in two separate experiments.534 Malaria Infection Inhibits HBV Replication and Gene Expression in Transgenic Mice
in endemic areas where both pathogens coexist at high fre-
quency. Indeed, in a study investigating the interactions be-
tween malaria and hepatitis B in Papua New Guinea, it has
been shown that patients with the highest rates of malaria
infection had the lowest prevalence of hepatitis B infection
(48). It is also noteworthy that viremia in chronic hepatitis B
infection appears to fluctuate in concert with Plasmodium fal-
ciparum infection (49), suggesting that the amount and type
of intrahepatic inflammatory cytokines induced by malaria
infection may influence the course of HBV infection in
man. Furthermore, mice infected with nonlethal strains of
P. yoelii and Plasmodium chabaudi have been shown to pro-
duce a stronger IFN-g response to infection than mice in-
fected with the respective lethal strains (23), suggesting that
the amount and quality of the inflammatory cytokines in-
duced in the liver might control those infections.
In conclusion, these results suggest that the inflammatory
cytokines induced and/or secreted by activated macro-
phages and the inflammatory cells they recruit into the liver
during malaria infection may play a pivotal role in the out-
come of coexisting HBV infection. These results not only
provide insight into the possible impact of malaria on HBV
replication in coinfected humans, they also suggest that
pharmacological strategies designed to activate the intra-
hepatic macrophage may have therapeutic merit during
chronic HBV infection.
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